Huy Gia Vuong1, Tam N M Ngo2, Hieu Trong Le3, Ian F Dunn4. 1. Department of Neurosurgery, Oklahoma University Health Sciences Center, Oklahoma City, OK, 73104, USA. 2. Faculty of Medicine, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, 700-000, Vietnam. 3. Department of Pathology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, 700-000, Vietnam. 4. Department of Neurosurgery, Oklahoma University Health Sciences Center, Oklahoma City, OK, 73104, USA. ian-dunn@ouhsc.edu.
Abstract
INTRODUCTION: Diffuse midline gliomas (DMGs) are infiltrative midline gliomas harboring H3K27M mutations and are generally associated with poor outcomes. H3K27M mutations include mutations in HIST1H3B/C (H3.1), HIST2H3B/D (H3.2), or H3F3A (H3.3) genes. It is still unclear whether these mutations each portend a universally poor prognosis, or if there are any factors which modulate outcome. The main objective of this study was to study overall survival (OS) of H3.1 versus H3.3 K27M-mutant DMGs in pediatric and adult patients. METHODS: PubMed and Web of Science were searched, and we included studies if they have individual patient data of DMGs with available H3K27M genotype. Kaplan-Meier analysis and Cox regression models were used to analyze the survival of H3.1 and H3.3 mutations in each subgroup. RESULTS: We included 26 studies with 102 and 529 H3.1 and H3.3-mutant DMGs, respectively. The H3.1 mutation was more commonly seen in younger age. In pediatric population, H3.3 mutation conferred a shorter survival (median OS of 10.1 vs 14.2 months; p < 0.001) in comparison to H3.1-positive patients, which was further confirmed in the multivariate Cox analysis. Conversely, H3.3 was associated with a prolonged survival in adult patients as compared with H3.1 mutation (median OS of 14.4 vs 1.7 months; p = 0.019). CONCLUSION: We demonstrated that the prognosis of H3.1 and H3.3 K27M mutation in DMG patients is modulated by patient age. Routine H3K27M mutation genotyping in newly diagnosed DMGs may further stratify patients with these difficult tumors.
INTRODUCTION: Diffuse midline gliomas (DMGs) are infiltrative midline gliomas harboring H3K27M mutations and are generally associated with poor outcomes. H3K27M mutations include mutations in HIST1H3B/C (H3.1), HIST2H3B/D (H3.2), or H3F3A (H3.3) genes. It is still unclear whether these mutations each portend a universally poor prognosis, or if there are any factors which modulate outcome. The main objective of this study was to study overall survival (OS) of H3.1 versus H3.3 K27M-mutant DMGs in pediatric and adult patients. METHODS: PubMed and Web of Science were searched, and we included studies if they have individual patient data of DMGs with available H3K27M genotype. Kaplan-Meier analysis and Cox regression models were used to analyze the survival of H3.1 and H3.3 mutations in each subgroup. RESULTS: We included 26 studies with 102 and 529 H3.1 and H3.3-mutant DMGs, respectively. The H3.1 mutation was more commonly seen in younger age. In pediatric population, H3.3 mutation conferred a shorter survival (median OS of 10.1 vs 14.2 months; p < 0.001) in comparison to H3.1-positive patients, which was further confirmed in the multivariate Cox analysis. Conversely, H3.3 was associated with a prolonged survival in adult patients as compared with H3.1 mutation (median OS of 14.4 vs 1.7 months; p = 0.019). CONCLUSION: We demonstrated that the prognosis of H3.1 and H3.3 K27M mutation in DMG patients is modulated by patient age. Routine H3K27M mutation genotyping in newly diagnosed DMGs may further stratify patients with these difficult tumors.
Authors: David N Louis; Caterina Giannini; David Capper; Werner Paulus; Dominique Figarella-Branger; M Beatriz Lopes; Tracy T Batchelor; J Gregory Cairncross; Martin van den Bent; Wolfgang Wick; Pieter Wesseling Journal: Acta Neuropathol Date: 2018-03-01 Impact factor: 17.088
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Alberto Picca; Giulia Berzero; Franck Bielle; Mehdi Touat; Julien Savatovsky; Marc Polivka; Elena Trisolini; Sheida Meunier; Yohann Schmitt; Ahmed Idbaih; Khe Hoang-Xuan; Jean-Yves Delattre; Karima Mokhtari; Anna Luisa Di Stefano; Marc Sanson Journal: Neurology Date: 2018-05-04 Impact factor: 9.910
Authors: John Lynes; Alvina A Acquaye; Hannah Sur; Anthony Nwankwo; Victoria Sanchez; Elizabeth Vera; Tianxia Wu; Brett Theeler; Terri S Armstrong; Mark R Gilbert; Edjah K Nduom Journal: J Neurooncol Date: 2020-07-23 Impact factor: 4.130
Authors: David N Louis; Arie Perry; Pieter Wesseling; Daniel J Brat; Ian A Cree; Dominique Figarella-Branger; Cynthia Hawkins; H K Ng; Stefan M Pfister; Guido Reifenberger; Riccardo Soffietti; Andreas von Deimling; David W Ellison Journal: Neuro Oncol Date: 2021-08-02 Impact factor: 13.029
Authors: Jessica D Schulte; Robin A Buerki; Sarah Lapointe; Annette M Molinaro; Yalan Zhang; Javier E Villanueva-Meyer; Arie Perry; Joanna J Phillips; Tarik Tihan; Andrew W Bollen; Melike Pekmezci; Nicholas Butowski; Nancy Ann Oberheim Bush; Jennie W Taylor; Susan M Chang; Philip Theodosopoulos; Manish K Aghi; Shawn L Hervey-Jumper; Mitchel S Berger; David A Solomon; Jennifer L Clarke Journal: Neurooncol Adv Date: 2020-10-22